Shares of the following exchange traded funds are trading more than 20 percent higher than 90 days ago, and they are within 10 percent of their 52-week highs. This set of ETFs provides a peek at areas investors have focused on in the third quarter, even as interest rates crept up, during the furor over possible military action in Syria, as well as the lead up to the government shutdown.
First Trust Global Wind Energy (NYSE:FAN) is trading more than 52 percent higher year to date and more than 28 percent higher than 90 days ago. This summer, the United States regained the lead in annual wind power capacity from China.
Continue Reading Below
The nondiversified fund seeks investment results that correspond to the price and yield of the ISE Global Wind Energy Index. It is a benchmark for investors interested in tracking public companies throughout the world that are active in the wind energy industry.
See also: Hedging Currency Risk With ETFs
First Trust ISE Chindia Index Fund (NYSE:FNI) has risen more than 28 percent in the past 90 days and reached a multiyear high last week. The Federal Reserve's surprise decision to keep quantitative easing in mid-September has helped boost emerging markets funds like this one.
The investment seeks results that correspond to the price and yield of the ISE ChIndia Index, a portfolio of 50 equities representing companies from China and India currently trading on U.S. exchanges. Top holdings in the ETF include Baidu (NASDAQ:BIDU) and Michael Kors (NYSE:KORS).
Global X FTSE Greece 20 ETF (NYSE:GREK) is up more than 36 percent in the past quarter and making another run at the 52-week high from last May. Clear signs that the declining Greek economy may be reaching bottom and overall rising confidence in Europe have boosted this ETF.
The investment seeks to provide results that correspond to the price and yield performance of the FTSE/Athex 20 Capped Index, which is designed to reflect broad-based equity market performance in Greece. Top holdings of the ETF include Coca-Cola Hellenic Bottling (NYSE:CCH) and National Bank of Greece (NYSE:NBG).
Global X NASDAQ China Technology ETF (NYSE:QQQC) is up more than 46 percent since the beginning of the year, most of that gain coming in the past three months. Technology has generally outperformed other sectors in the Chinese market this year.
The investment seeks to provide results that correspond to the price and yield performance of the NASDAQ OMX China Technology Index, which invests primarily in securities of technology companies that are domiciled in, principally traded in or with revenues that come chiefly from China.
Global X Social Media Index ETF (NYSE:SOCL) is trading more than 34 percent higher than three months ago and more than 54 percent higher year-to-date. Social media companies like Facebook (NASDAQ:FB) posted strong results and bullish outlooks in the third quarter.
This investment seeks to capture the global industry in a single ETF. It includes companies from all over the world that provide social networking, file sharing and other Web-based media applications. Top holdings include Facebook, Sina (NASDAQ:SINA) and LinkedIn (NYSE:LNKD).
Guggenheim Solar ETF (NYSE:TAN) is nearly 120 percent higher than at the beginning of the year . Some experts see nine percent or more further upside, as demand for photovoltaic cells rises and the Chinese government supports the industry.
The investment seeks results that correspond to the performance of the MAC Global Solar Energy Index. Top holdings in the ETF include Trina Solar (NYSE:TSL), First Solar (NASDAQ:FSLR) and GT Advanced Technologies (NASDAQ:GTAT).
ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) is about 118 percent higher year to date, as well as up about 35 percent in the past three months. Strength in the biotech sector is well over a year old, despite some head winds.
The investment seeks daily investment results that correspond to twice the daily performance of the Nasdaq Biotechnology Index, which is a modified capitalization weighted index that includes securities of Nasadaq- listed companies classified as either biotechnology or pharmaceutical.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.